/BNGO
Bionano Genomics, Inc.
BNGO • NASDAQBNGO • NASDAQ • Healthcare
$1.12-2.61%-0.03
$1.12-2.61%(-0.03)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
100Bullish
Risk
51Moderate
Momentum
0Negative
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
1.2%▼25.3pp
Revenue after COGS
Operating
-337.9%▲258.1pp
After operating expenses
Net
-364.0%▲279.8pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
-0.3
Price vs earnings
EV/EBITDA
-0.5
Enterprise value
FCF Yield
-209.7%
Cash generation
Earnings Yield
-340.3%
Inverse of P/E
Capital Efficiency
-207
GoAI Quality ScorePoor
ROEReturn on Equity
-316.7%Weak
ROAReturn on Assets
-146.1%Weak
ROICReturn on Invested Capital
-165.2%Weak
Financial Health
Current RatioAdequate
1.06
Short-term solvency (>1.5)
Net Debt / EBITDANet Cash
-0.19x
Debt repayment capacity (<3x)
Income QualityFair
0.62
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $30.78M | $36.12M | $27.80M | $17.98M | $8.50M |
| Gross Profit | $380.00K | $9.57M | $5.95M | $3.87M | $2.77M |
| Gross Margin | 1.2% | 26.5% | 21.4% | 21.5% | 32.6% |
| Operating Income | -$103.98M | -$215.25M | -$131.70M | -$77.10M | -$38.55M |
| Net Income | -$112.02M | -$232.49M | -$132.60M | -$72.44M | -$41.11M |
| Net Margin | -364.0% | -643.7% | -476.9% | -402.8% | -483.4% |
| EPS | -$88.13 | -$24508.80 | -$16505.40 | -$9421.20 | -$14194.80 |
Average Price Target
$46.50▲ 4051.8% Upside
Past 12 Months
12 Month Forecast
Based on 25 Wall Street analysts offering 12 month price targets for Bionano Genomics, Inc., the average price target is $46.50, with a high forecast of $175.00 and a low forecast of $1.00. The average price target represents a 4051.8% increase from the current price of $1.12.
Highest
$175.00
Average
$46.50
Lowest
$1.00
Rating Distribution
Strong Buy
0
0%
Buy
4
57%
Hold
3
43%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
HC Wainwright & Co.● Maintain
Buy
2025-11-24HC Wainwright & Co.● Maintain
Buy
2025-08-18Maxim Group▲ Upgrade
Hold→Buy
2025-05-20Scotiabank● Maintain
Sector Perform
2025-04-02Ladenburg Thalmann▼ Downgrade
Buy→Neutral
2024-11-15BTIG● Maintain
Buy
2024-05-16Scotiabank● Maintain
Sector Outperform
2024-03-07Maxim Group▼ Downgrade
Buy→Hold
2023-11-13BTIG● Maintain
Buy
2023-08-10BTIG● Maintain
Buy
2023-08-09Earnings History & Surprises
BEAT RATE
22%
Last 18 quarters
AVG SURPRISE
-1412.4%
EPS vs Estimate
BEATS / MISSES
4/14
Last 18 quarters
LATEST EPS
$-1.59
Q4 '25
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q4 '25
+12.2%
$-1.59 vs $-1.81
Q3 '25
+26.0%
$-1.99 vs $-2.69
Q2 '25
+67.0%
$-1.15 vs $-3.49
Q1 '25
-858.2%
$-57.49 vs $-6.00
Q4 '24
-9023.8%
$-19.16 vs $-0.21
Q3 '24
-3321.4%
$-14.37 vs $-0.42
Q2 '24
-5514.1%
$-35.93 vs $-0.64
Q1 '24
-6508.0%
$-57.49 vs $-0.87
Q4 '23
-97.3%
$-88.62 vs $-44.91
Q3 '23
-37.8%
$-74.25 vs $-53.89
Q2 '23
-33.3%
$-71.86 vs $-53.89
Q1 '23
-44.4%
$-77.84 vs $-53.89
No investor questions available.
Latest News
No news available